IncobotulinumtoxinA 100 UNT Injection [Xeomin] — Competitive Intelligence Brief

IncobotulinumtoxinA 100 UNT Injection [Xeomin] (IncobotulinumtoxinA 100 UNT Injection [Xeomin]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology, Dermatology, Aesthetics.

phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology, Dermatology, Aesthetics Small molecule

Target snapshot

IncobotulinumtoxinA 100 UNT Injection [Xeomin] (IncobotulinumtoxinA 100 UNT Injection [Xeomin]) — University Of Perugia. IncobotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IncobotulinumtoxinA 100 UNT Injection [Xeomin] TARGET	IncobotulinumtoxinA 100 UNT Injection [Xeomin]	University Of Perugia	phase 3	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxin A	Onabotulinumtoxin A	Wake Forest University Health Sciences	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 100 UNT	OnabotulinumtoxinA 100 UNT	University of South Florida	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinum Toxin A	Onabotulinum Toxin A	Walter Reed National Military Medical Center	marketed	Botulinum toxin	SNAP-25 (synaptosome-associated protein of 25 kDa)
Intradetrusor Botox Injections	Intradetrusor Botox Injections	The Methodist Hospital Research Institute	marketed	Neurotoxin; botulinum toxin type A	SNARE complex (synaptosomal-associated protein); acetylcholine release machinery
Chemodenervation (4 months)	Chemodenervation (4 months)	University of Wisconsin, Madison	marketed	Botulinum toxin	SNARE complex (synaptobrevin, SNAP-25, syntaxin)
OnabotulinumtoxinA 100 UNT [Botox]	OnabotulinumtoxinA 100 UNT [Botox]	Women and Infants Hospital of Rhode Island	marketed	Neurotoxin; botulinum toxin type A	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

1. Galderma R&D · 2 drugs in this class
2. Hexsel Dermatology Clinic · 2 drugs in this class
3. Seoul National University Hospital · 2 drugs in this class
4. University of Utah · 2 drugs in this class
5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
6. EuBiologics Co.,Ltd · 1 drug in this class
7. Allergan · 1 drug in this class
8. GlaxoSmithKline · 1 drug in this class
9. Beth Israel Deaconess Medical Center · 1 drug in this class
10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class